Treatment of Rheumatoid Arthritis with a Novel siRNA-IgG Conjugate


Though the therapeutics currently available for the treatment of rheumatoid arthritis (RA) have dramatically improved the lives of patients, a large subset of patients show little to no response to treatment. Dr Band and colleagues have identified novel targets in the complement system for the treatment of rheumatoid arthritis (RA). Previous work from this group has demonstrated the importance of C5-C5ar in RA, demonstrating viable targets for treatment. Dr Banda aims on utilizing a combined approach of blocking transcription through siRNA and inhibiting pathway signaling through a siRNA-antibody conjugate.


Download Summary Document Here:

For Information, Contact:
Mary Tapolsky
University of Colorado
Nirmal Banda
V. Michael Holers
Disease Areas:
For inquiries, email:     © 2024. All Rights Reserved. Powered by Inteum